NCT05497570View on ClinicalTrials.gov

Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

November 7, 2021

Study Completion Date

April 21, 2022

Conditions
Arthrocentesis
Interventions
DRUG

Tenoxicam Injectable Product

After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint

Trial Locations (1)

25240

Ataturk University, Erzurum

All Listed Sponsors
lead

Ataturk University

OTHER

NCT05497570 - Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis | Biotech Hunter | Biotech Hunter